Travis Wilson

Managing Director, Carlyle

Travis Wilson is a Managing Director focused on our US Buyout & Growth and clinical co-development opportunities in the healthcare sector. He is based in Boston.

Travis has more than 20 years of healthcare investing and executive experience from private equity to venture capital. Prior to Carlyle, Travis was a Growth Partner with Flagship Pioneering, where he held board and leadership roles on development and commercial-stage biotech companies, including Valo Health, Mirai Bio, and Harbinger Health.

Prior to Flagship, Travis was a Managing Partner at Gurnet Point Capital, a life sciences private equity fund specializing in US buyouts, including the privatization of commercial biotech companies. During his Gurnet Point tenure, he also served as a board member of Boston Pharmaceuticals, focusing on the development of efimosfermin for MASH.

Travis was previously the CEO of Stealth BioTherapeutics, a mitochondrial-focused company, developing Forzinity for Barth syndrome. While CEO, and for more than a decade, Travis was a member of the Morningside venture capital team where he worked on BioVex, Liquidia, ACD, and Apellis.

Travis received his JD and a BS in Chemical Engineering, both from the University of Wisconsin.